The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity
Open accessAbstract
The chemosensitising effects of poly(ethylene oxide)-poly(propylene oxide)-poly-(ethylene oxide) (PEO-PPO-PEO) block copolymers (Pluronic) in multidrug-resistant cancer cells has been described recently (Alakhov VY, Moskaleva EY, Batrakova EV, Kabanov AV 1996, Biocon. Chem., 7, 209). This paper presents initial studies on in vivo evaluation of Pluronic copolymers in the treatment of cancer. The anti-tumour activity of epirubicin (EPI) and doxorubicin (DOX), solubilised in micelles of Pluronic L61, P85 and F108, was investigated using murine leukaemia P388 and daunorubicin-sensitive Sp2/0 and -resistant Sp2/0(DNR) myeloma cells grown subcutaneously (s.c.). The study revealed that the lifespan of the animals and inhibition of tumour growth were considerably increased in mice treated with drug/copolymer compositions compared with animals treated with the free drugs. The anti-tumour activity of the drug/copolymer compositions depends on the concentration of the copolymer and its hydrophobicity, as determined by the ratio of the lengths of hydrophilic PEO and hydrophobic PPO segments. The data suggest that higher activity is associated with more hydrophobic copolymers. In particular, a significant increase in lifespan (T/C> 150%) and tumour growth inhibition (> 90%) was observed in animals with Sp2/0 tumours with EPI/P85 and DOX/L61 compositions. The effective doses of these compositions caused inhibition of Sp2/0 tumour growth and complete disappearance of tumour in 33-50% of animals. Future studies will focus on the evaluation of the activity of Pluronic-based compositions against human drug-resistant tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kabanov, A. V., Nazarova, I. R., Astafieva, I. V., Batrakova, E. V., Alakhov, V. Y., Yaroslavov, A. A., & Kabanov, V. A. (1995) · Macromolecules · doi:10.1021/ma00111a026 · Cited by 459
Self-citationKabanov, A. V., Chekhonin, V. P., Alakhov, V. Y., Batrakova, E. V., Lebedev, A. S., Melik-Nubarov, N. S., Arzhakov, S. A., Levashov, A. V., Morozov, G. V., Severin, E. S., et al. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)81689-8 · Cited by 296
Self-citationWatersoluble polymers in medicine
Bader, H., Ringsdorf, H., & Schmidt, B. (1984) · Die Angewandte Makromolekulare Chemie · doi:10.1002/apmc.1984.051230121 · Cited by 291
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
“Drugs, such as diazepam and indomethacin (123,124), adriamicin (90,125Y127), anthracycline antibiotics (128), polynucleotides (129,130), and doxorubicin (131) were effectively solubilized by various polymeric micelles, including Pluronic (block co-polymers of PEG and polypropelene glycol) (52).”
BackgroundStructure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822
Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00009-3 · Cited by 1,474
Self-citationNanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging
Parveen, S., Misra, R., & Sahoo, S. K. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.05.016 · Cited by 1,436
Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278
“Formulation of Dox, paclitaxel or other drugs with Pluronics also resulted in enhancement of drug anticancer effect in in vivo tumor models [22,31-33].”
BackgroundSelf-citationPolymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery
Lavasanifar, A., Samuel, J., & Kwon, G. S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00015-7 · Cited by 756
Pluronic® block copolymers for overcoming drug resistance in cancer
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00047-9 · Cited by 636
Self-citationP-glycoprotein Inhibition for Optimal Drug Delivery
Amin, M. L. (2013) · Drug Target Insights · doi:10.4137/dti.s12519 · Cited by 624
Nanotechnology in Therapeutics: A Focus on Nanoparticles as A Drug Delivery System
Bamrungsap, S., Zhao, Z., Chen, T., Wang, L., Li, C., Fu, T., & Tan, W. (2012) · Nanomedicine · doi:10.2217/nnm.12.87 · Cited by 606
Polymeric micelles drug delivery system in oncology
Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.012 · Cited by 570
Chiappetta, D. A., & Sosnik, A. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.03.022 · Cited by 567
Targeted polymeric micelles for delivery of poorly soluble drugs
Torchilin, V. P. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4153-5 · Cited by 543
Micelles and nanoparticles for ultrasonic drug and gene delivery
Husseini, G. A., & Pitt, W. G. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.008 · Cited by 468
Polymeric micelles for drug delivery
Aliabadi, H. M., & Lavasanifar, A. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.139 · Cited by 446
Wei, Z., Hao, J., Yuan, S., Li, Y., Juan, W., Sha, X., & Fang, X. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.030 · Cited by 427
Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
Edis, Z., Wang, J., Waqas, M. K., Ijaz, M., & Ijaz, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s289443 · Cited by 390
Polymeric micellar pH-sensitive drug delivery system for doxorubicin
Hrubý, M., Koňák, Č., & Ulbrich, K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.11.017 · Cited by 385
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
“Of particular note is the evidence of antitumour activity of SP1049C in doxorubicin-resistant tumours (Batrakova et al, 1996) and in multiple drug resistance (MDR) cells (Venne et al, 1996; Alakhov et al, 1999).”
BackgroundSelf-citationPluronic® block copolymers: novel functional molecules for gene therapy
Kabanov, A. V., Lemieux, P., Vinogradov, S., & Alakhov, V. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00018-2 · Cited by 375
Self-citationNanoparticles as carriers for drug delivery in cancer
Dadwal, A., Baldi, A., & Kumar Narang, R. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2018.1457039 · Cited by 335
Mohan, P., & Rapoport, N. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100269f · Cited by 331
Kabanov, A. V., Batrakova, E. V., & Miller, D. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00176-x · Cited by 325
Self-citationBlock copolymer-based formulation of doxorubicin. From cell screen to clinical trials
Alakhov, V., Klinski, E., Li, S., Pietrzynski, G., Venne, A., Batrakova, E., Bronitch, T., & Kabanov, A. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00064-8 · Cited by 266
Self-citationPolymeric micelles in oral chemotherapy
Bromberg, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.018 · Cited by 264
Nanotechnology in Cancer Drug Delivery and Selective Targeting
Sutradhar, K. B., & Amin, M. L. (2014) · ISRN Nanotechnology · doi:10.1155/2014/939378 · Cited by 241
Ultrasonically triggered drug delivery: Breaking the barrier
Husseini, G. A., Pitt, W. G., & Martins, A. M. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.07.051 · Cited by 87
Ultrasonic-activated micellar drug delivery for cancer treatment
Husseini, G. A., & Pitt, W. G. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21444 · Cited by 83
Metadata
- Authors
- Batrakova, E., Dorodnych, T., Klinskii, E., Kliushnenkova, E., Shemchukova, O., Goncharova, O., Arjakov, S., Alakhov, V., & Kabanov, A.
- Venue
- British Journal of Cancer
- Published
- 1996-11
- Volume
- 74
- Issue
- 10
- Pages
- 1545-1552
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1993895985
- Cited by
- 228
- References
- 3
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.